RecruitingInterventionalPhase 1Last updated Aug 13, 2026

YMN-136 Vaccine for Patients With Advanced Hepatobiliary and Pancreatic Malignancies

YMN-136 Vaccine for Patients With Advanced Hepatobiliary and Pancreatic Malignancies: A Prospective, Phase I Clinical Trial

Overview

ClinicalTrials.gov ID: NCT07763301
Lead Sponsor: West China HospitalOTHER
Brief Summary: This study aims to determine the safety and maximum tolerated dose (MTD) of YMN-136 vaccine through a dose escalation trial, and to investigate whether YMN-136 vaccine can assist in the treatment of patients with advanced hepatobiliary and pancreatic malignancies.
Study Type: Interventional

Status

Overall Status: Recruiting
Start Date: Aug 1, 2026Actual
Primary Completion Date: Feb 29, 2028Estimated
Completion Date: May 31, 2028Estimated

Study Record Dates

First Submitted: Aug 10, 2026
First Submitted that Met QC Criteria: Aug 10, 2026
First Posted: Aug 13, 2026Actual
Last Update Submitted that Met QC Criteria: Aug 10, 2026
Last Update Posted: Aug 13, 2026Actual
Last Verified: Aug 2026

NCT07409805Recruiting

YMN-136 Vaccine for Patients With Liver Metastasis of Colorectal Cancer Progressing After Third-Line Treatment

NCT07567222Recruiting

Clinical Study of Novel Therapeutic Vaccine for Advanced Solid Tumors

NCT07580261Not yet recruiting

YMN-A02 for Advanced Primary Hepatocellular Carcinoma.

NCT07610707Not yet recruiting

YMN-A02 for Advanced pMMR Colorectal Cancer With Liver Metastases

NCT06927297Recruiting

Phase I Study of the Safety, Tolerability, and Efficacy of an Engineered Mitochondrial Vaccine in Advanced Solid Tumors

NCT07594964Recruiting

To Evaluate the Safety, Tolerability, and Preliminary Efficacy of XH001 Injection as Adjuvant Therapy in Patients With High-risk Recurrent Solid Tumors